Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 5/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | WNT1 | P04628 | 6/20 | 0.41 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.40 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.40 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL31243436 | 1.00 | GSK3B (0.45) | GSK3BCYP1A2GSK3AKDRDYRK1A | |
| Trifluoroacetic Acid SCHEMBL31243719 | 0.86 | AAK1 (0.49) | GSK3BGSK3AKDRDYRK1AWNT1 | |
| Trifluoroacetic Acid SCHEMBL26130936 | 0.86 | AAK1 (0.49) | GSK3BGSK3AKDRDYRK1AWNT1 | |
| Hydrochloric Acid SCHEMBL26129838 | 0.86 | GSK3B (0.54) | GSK3BCYP1A2GSK3AKDRDYRK1A | |
| Trifluoroacetic Acid SCHEMBL26128579 | 0.85 | GSK3B (0.45) | GSK3BGSK3AKDRDYRK1AWNT1 | |
| Trifluoroacetic Acid SCHEMBL31243591 | 0.85 | GSK3B (0.45) | GSK3BGSK3AKDRDYRK1AWNT1 | |
| SCHEMBL26394543 | 0.84 | DYRK1A (0.48) | GSK3BGSK3AKDRDYRK1ACDK2 | |
| Hydrochloric Acid SCHEMBL26129195 | 0.83 | DYRK1A (0.47) | GSK3BGSK3AKDRDYRK1ACDK2 | |
| SCHEMBL26394375 | 0.83 | GSK3B (0.51) | GSK3BGSK3AKDRDYRK1ACDK2 | |
| Hydrochloric Acid SCHEMBL26130354 | 0.82 | GSK3B (0.50) | GSK3BGSK3AKDRDYRK1ACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | claimed |
| EP-4499612-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2025-02-05 | — | — | EP | claimed |
| WO-2023186773-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-05 | — | — | WO | claimed |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| EP-4499612-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023186773-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | CDK1, CDK11A, CDK3 | GSK3B 90/4885CYP1A2 4157/4885GSK3A 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.